Related references
Note: Only part of the references are listed.IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer
Margaux Hubert et al.
SCIENCE IMMUNOLOGY (2020)
Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naive and memory NY-ESO1-specific CD8+ T cells
Kelly-Anne Masterman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
IL-12 from endogenous cDC1, and not vaccine DC, is required for Th1 induction
DiyaaElDin Ashour et al.
JCI INSIGHT (2020)
Targeting Antigens to Different Receptors on Conventional Type 1 Dendritic Cells Impacts the Immune Response
Even Fossum et al.
JOURNAL OF IMMUNOLOGY (2020)
cDC1 prime and are licensed by CD4+T cells to induce anti-tumour immunity
Stephen T. Ferris et al.
NATURE (2020)
Display of Native Antigen on cDC1 That Have Spatial Access to Both T and B Cells Underlies Efficient Humoral Vaccination
Yu Kato et al.
JOURNAL OF IMMUNOLOGY (2020)
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets
Nina Bhardwaj et al.
NATURE CANCER (2020)
Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141+dendritic cells to activate naive and memory WT1-specific CD8+T cells
Frances E. Pearson et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)
Dendritic cells in cancer immunology and immunotherapy
Stefanie K. Wculek et al.
NATURE REVIEWS IMMUNOLOGY (2020)
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
Kalijn F. Bol et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Trial watch: dendritic cell vaccination for cancer immunotherapy
Jenny Sprooten et al.
ONCOIMMUNOLOGY (2019)
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
Akihiro Tsuboi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Boettcher et al.
CELL (2018)
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C. Barry et al.
NATURE MEDICINE (2018)
Myosin II Synergizes with F-Actin to Promote DNGR-1-Dependent Cross-Presentation of Dead Cell-Associated Antigens
Oliver Schulz et al.
CELL REPORTS (2018)
Notch Signaling Facilitates In Vitro Generation of Cross-Presenting Classical Dendritic Cells
Margaret E. Kirkling et al.
CELL REPORTS (2018)
Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study
Sumiyuki Nishida et al.
CANCER IMMUNOLOGY RESEARCH (2018)
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Remy Thomas et al.
FRONTIERS IN IMMUNOLOGY (2018)
Large-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity
Sreekumar Balan et al.
CELL REPORTS (2018)
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Elizabeth A. Griffiths et al.
CLINICAL CANCER RESEARCH (2018)
Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Anje Cauwels et al.
CANCER RESEARCH (2018)
High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization
Marcela Alcantara-Hernandez et al.
IMMUNITY (2017)
Phenotypic and functional consequences of different isolation protocols on skin mononuclear phagocytes
Rachel A. Botting et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2017)
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
Abhishek D. Garg et al.
TRENDS IN IMMUNOLOGY (2017)
Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells
Hae-Young Park et al.
NPJ VACCINES (2017)
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
Sebastien Anguille et al.
BLOOD (2017)
Lineage specification of human dendritic cells is marked by IRF8 expression in hematopoietic stem cells and multipotent progenitors
Jaeyop Lee et al.
NATURE IMMUNOLOGY (2017)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger et al.
CANCER CELL (2017)
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study
M. Higgins et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Liver-Resident Memory CD8+ T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection
Daniel Fernandez-Ruiz et al.
IMMUNITY (2016)
IFN-λ cancer immunotherapy: new kid on the block
Ahmed Lasfar et al.
IMMUNOTHERAPY (2016)
Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+ T cell recognition
Kirsteen M. Tullett et al.
JCI INSIGHT (2016)
Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers
N. Anandasabapathy et al.
BONE MARROW TRANSPLANTATION (2015)
Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions
Sarah Eickhoff et al.
CELL (2015)
Human dendritic cell subsets and function in health and disease
Meredith O'Keeffe et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates
Jessica Li et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
Spatiotemporally Distinct Interactions with Dendritic Cell Subsets Facilitates CD4+ and CD8+ T Cell Activation to Localized Viral Infection
Jyh Liang Hor et al.
IMMUNITY (2015)
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
Miranda L. Broz et al.
CANCER CELL (2014)
Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205
Madhav V. Dhodapkar et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The dual role of IRF8 in cancer immunosurveillance
Giovanna Schiavoni et al.
ONCOIMMUNOLOGY (2013)
The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells
Gerty Schreibelt et al.
BLOOD (2012)
F-Actin Is an Evolutionarily Conserved Damage-Associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells
Susan Ahrens et al.
IMMUNITY (2012)
The Dendritic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments
Jian-Guo Zhang et al.
IMMUNITY (2012)
The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice
Santiago Zelenay et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
Mercedes B. Fuertes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Mark S. Diamond et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans
Marina Caskey et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Targeting Antigen to Mouse Dendritic Cells via Clec9A Induces Potent CD4 T Cell Responses Biased toward a Follicular Helper Phenotype
Mireille H. Lahoud et al.
JOURNAL OF IMMUNOLOGY (2011)
Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A
Juliana Idoyaga et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens
Sarah L. Jongbloed et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant
M. Paula Longhi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Identification of a dendritic cell receptor that couples sensing of necrosis to immunity
David Sancho et al.
NATURE (2009)
The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement
Irina Caminschi et al.
BLOOD (2008)
WT1 peptide vaccine for the treatment of cancer
Yoshihiro Oka et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes
Cristal Huysamen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin
David Sancho et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Share Paper
